期刊文献+

1例高血压伴低血钾患者降压药物对醛固酮肾素活性比值的影响分析及应对策略 被引量:4

Effect Analysis and Countermeasures for Antihypertensive Drugs on Aldosterone Renin Ratio of a Patient with Hypertension and Hypokalemia
原文传递
导出
摘要 高血压伴持续性低血钾或难治性高血压应筛查原发性醛固酮增多症,常将醛固酮肾素活性比值作为筛查指标,本文通过临床药师参与1例高血压伴低血钾患者的降压方案调整,测定血浆醛固酮和肾素活性水平的比值(ARR),分析不同类型降压药物对ARR的影响,并对降压用药方案进行调整。阐述了临床药师深入临床,通过监测药物不良反应及临床疗效进行药学监护,有助于提高药学服务质量,促进药物合理使用。 Persistent hypokalemia or refractory hypertension should perform primary aldosteronism screening with the aldosterone renin activity ratio as the screening index. Clinical pharmacists participated in the antihypertensive scheme adjustment for a patient with hypertension associated with hypokalemia by determining the level of plasma aldosterone and renin activity ratio( ARR),analyzing the influence of the different types of antihypertensive drugs on ARR and adjusting the scheme of antihypertensive drugs. The paper expounded that clinical pharmacists can monitor the adverse drug reactions and clinical efficacy deeply in clinical practice and carry out pharmaceutical care,which is helpful to improving the quality of pharmaceutical care and promoting the rational drug use.
作者 马红妹 常德玉 侯幸赟 陶霞 陈万生 Ma Hongmei;Chang Deyu;Hou Xingyun;Tao Xia;Chen Wansheng(Department of Pharmacy,Changzheng Hospital,Shanghai 200003,China;Department of Pharmacy,People1's Hospital of Rizhao)
出处 《中国药师》 CAS 2020年第4期680-681,共2页 China Pharmacist
基金 上海市卫生计生系统重要薄弱学科建设计划资助项目(编号:2016ZB0303)。
关键词 降压药 醛固酮肾素活性比值 应对策略 药学监护 Antihypertensive drug Aldosterone renin ratio Countermeasures Pharmaceutical care
  • 相关文献

参考文献6

二级参考文献79

  • 1刘雪娜,周宪梁,刘亚欣,顾晴,陈改玲,孙晓昕,丰雷,惠汝太.原发性醛固酮增多症合并高血浆肾素活性的临床病例分析[J].中国分子心脏病学杂志,2004,4(4):233-234. 被引量:1
  • 2Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab, 2004,89 : 1045-1050.
  • 3Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab, 2000,85:2854-2859.
  • 4Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coil Cardiol, 2006,48:2293-2300.
  • 5Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension, 2002,40:892-896.
  • 6Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care, 2007,30 : 1699-1703.
  • 7Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol, 2005,45 : 1243-1248.
  • 8Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism : results of the PAPY Study. Hypertension, 2006,48 : 232-238.
  • 9Pessina AC, Sacchetto A, Rossi GP. Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension. Adv Exp Med Biol, 1997,432:63-69.
  • 10Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism : need for a standardized protocol. J Hypertens, 2006,24:737-745.

共引文献67

同被引文献79

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部